Molecular Biomedicine, launched in 2020, is a peer-reviewed, open access journal published annually. It is a collaborative venture between the globally renowned scientific publishing company Springer Nature and the Sichuan Association for the Promotion of International Medical Exchange. This journal is dedicated to publishing high-quality research in the field of biomedicine from a molecular perspective, encompassing both fundamental and clinical studies.

Focusing on the mechanisms of human disease, as well as advancements in prevention, diagnosis, and treatment, Molecular Biomedicine aims to become a leading international academic journal with a significant impact in the biomedicine sector. The journal's commitment to open access ensures that its content is widely accessible, fostering global exchange of scientific knowledge and accelerating the dissemination of breakthroughs in molecular medicine.By embracing innovative research methodologies and interdisciplinary approaches, Molecular Biomedicine is positioned to contribute to the advancement of medical science, offering insights that could potentially lead to improved healthcare outcomes. The journal's editorial board, composed of experts from around the world, ensures that the published work meets the highest standards of scientific rigor and integrity, solidifying its reputation as a trusted source of information in the scientific community.

《分子生物医学》于2020年创刊，是一本同行评审、每年出版一卷的开放获取期刊。这是全球知名的科学出版公司Springer Nature与四川省国际医学交流促进会合作创立的。该期刊致力于发表从分子角度出发的高质量生物医学研究，包括基础和临床研究。专注于人类疾病的机制，以及在预防、诊断和治疗方面的进展，杂志旨在成为在生物医学领域具有重要国际影响力的学术期刊。期刊对开放获取的承诺确保了其内容的广泛可及性，促进了科学知识的全球交流，并加速了分子医学突破的传播。

通过采用创新的研究方法和跨学科的方法，杂志有望为医学科学的进步做出贡献，提供可能带来改善医疗结果的洞察。由世界各地的专家组成的期刊编委会确保发表的工作达到最高的科学严谨性和诚信标准，巩固了其作为科学界值得信赖的信息来源的声誉。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映Biochemistry, Genetics and Molecular Biology-Molecular Medicine领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为6.3，平均审稿速度为 10 Weeks ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。